← Leaderboards
Partha Roy
University Of Pittsburgh At Pittsburgh
$5,696,734
Attributed
$6,016,458
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $905.4K · FY2006–25$1M$750K$500K$250K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,016,458 · 4
By mechanism
R01$5,590,159 · 3
R21$426,299 · 1
Top collaborators
- Donna M Huryn2 shared
- David Ryan Koes2 shared
- Andrew Paul Vandemark2 shared
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Gerald R Hammond$3,995,467
- Abigail Elizabeth Allen Gondringer$103,392
- Vanathi Gopalakrishnan$3,490,994
- David Ryan Koes$4,131,008
- David Martin Gau$750,094
Others in their field
Top investigators on “In Vitro”
- David Heimbrook · Leidos Biomedical Research, Inc.$553,787,942
- Leonard Freedman · Leidos Biomedical Research, Inc.$310,441,779
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,686,873
- Dennis R. Burton · Scripps Research Institute$79,204,175
Research focus
In VitroCytoskeletonIn VivoCellsActinsBreast Cancer CellNeoplastic CellNeoplasm MetastasisLinkRegulationActin-Binding ProteinCell MotilitySignal TransductionProfilinFamilyDown-RegulationMolecularInsightProteinsVasodilator-Stimulated PhosphoproteinMouse ModelMalignant Breast NeoplasmPathway InteractionsLead
Grant awards (23)
Transcriptional Regulation of Dormancy and Emergence in Breast Cancer$377,929
R01 · FY2025 · CA · contact PI
Profilin biology in breast cancer$338,236
R01 · FY2025 · CA · contact PI
Transcriptional Regulation of Dormancy and Emergence in Breast Cancer$399,784
R01 · FY2024 · CA · contact PI
Profilin biology in breast cancer$381,058
R01 · FY2024 · CA · contact PI
Transcriptional Regulation of Dormancy and Emergence in Breast Cancer$401,019
R01 · FY2023 · CA · contact PI
Profilin biology in breast cancer$348,847
R01 · FY2023 · CA · contact PI
Discovery of Cell-based Chemical Probes Targeting Aberrant Angiogenesis in the Eye$155,520
R21 · FY2023 · EY · contact PI
Profilin biology in breast cancer$345,706
R01 · FY2022 · CA · contact PI
Discovery of Cell-based Chemical Probes Targeting Aberrant Angiogenesis in the Eye$270,779
R21 · FY2022 · EY · contact PI
Profilin biology in breast cancer$348,585
R01 · FY2021 · CA · contact PI
Profilin as a target to suppress Invasive breast cancer$46,538
R01 · FY2017 · CA · contact PI
Profilin as a target to suppress Invasive breast cancer$257,843
R01 · FY2016 · CA · contact PI
Profilin as a target to suppress Invasive breast cancer$257,843
R01 · FY2015 · CA · contact PI
Profilin as a target to suppress Invasive breast cancer$250,108
R01 · FY2014 · CA · contact PI
Profilin as a target to suppress Invasive breast cancer$264,482
R01 · FY2013 · CA · contact PI
Profilin as a target to suppress Invasive breast cancer$258,797
R01 · FY2012 · CA · contact PI
Profilin as a target to suppress invasive breast cancer$248,922
R01 · FY2010 · CA · contact PI
Profilin as a target to suppress invasive breast cancer$247,083
R01 · FY2009 · CA · contact PI
Profilin as a target to suppress invasive breast cancer$245,328
R01 · FY2008 · CA · contact PI
Profilin as a target to suppress invasive breast cancer$38,862
R01 · FY2008 · CA · contact PI
Profilin as a target to suppress invasive breast cancer$250,594
R01 · FY2007 · CA · contact PI
Profilin as a target to suppress invasive breast cancer$33,126
R01 · FY2007 · CA · contact PI
Profilin as a target to suppress invasive breast cancer$249,469
R01 · FY2006 · CA · contact PI